Repros Therapeutics (RPRX) Tops Q3 EPS by 1c

Repros Therapeutics (NASDAQ: RPRX) reported Q3 EPS of ($0.17), $0.01 better than the analyst estimate of ($0.18). Revenue for the quarter came in at $10 thousand versus the consensus estimate of $1 thousand.

The Company had cash and cash equivalents of approximately $10.5 million as of September 30, 2016 as compared to $21.4 million as of December 31, 2015. Net cash of approximately $12.5 million and $20.5 million was used in operating activities during the nine month periods ended September 30, 2016 and 2015, respectively. The major use of cash for operating activities for the nine month period ended September 30, 2016 was to fund our clinical development programs and associated administrative costs. No cash was used in investing activities during the nine month period ended September 30, 2016. Cash provided by financing activities for the nine month period ended September 30, 2016 was approximately $1.6 million due to the 807,340 ATM Shares sold at a weighted average share price of $2.15, net of related expenses.

For earnings history and earnings-related data on Repros Therapeutics (RPRX) click here.

You May Also Be Interested In

• TechnipFMC (FTI) Tops Q1 EPS by 6c, provides guidance
• Asbury Automotive Group (ABG) Misses Q1 EPS by 55c
• Keurig Dr Pepper Inc. (KDP) Tops Q1 EPS by 3c; confirms guidance